^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
tidutamab (XmAb18087)
i
Other names: XmAb18087, XmAb 18087
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Xencor
Drug class:
CD3 agonist, SSTR2 inhibitor
Related drugs:
3years
[VIRTUAL] Safety, Pharmacodynamic, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Subjects with Advanced Neuroendocrine Tumors (NANETS 2021)
Tidutamab was generally well tolerated with disease control in >50% of evaluable NET subjects. Additional studies in other tumors that express SSTR2 are warranted, and poor outcomes in subjects with higher PD(L)-1 expression suggest combinations with checkpoint inhibitors should be considered.
Clinical • PK/PD data • PD(L)-1 Biomarker • IO biomarker
|
SSTR (Somatostatin Receptor) • CD4 (CD4 Molecule) • SSTR2 (Somatostatin Receptor 2)
|
PD-1 expression • SSTR2 expression
|
tidutamab (XmAb18087)
Share via
